Clinical Trials Logo

Hepatic Cyst clinical trials

View clinical trials related to Hepatic Cyst.

Filter by:
  • None
  • Page 1

NCT ID: NCT04111692 Recruiting - Clinical trials for Autosomal Dominant Polycystic Kidney

A Prospective Observational Study of Foam Sclerotherapy .

Start date: November 6, 2017
Phase:
Study type: Observational

An observational prospective study to determine the impact of foam sclerotherapy of large, dominant kidney/liver cysts on quality of life outcomes and kidney/liver cyst volumes at up to 12 months of follow-up in patients with autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD).

NCT ID: NCT02368015 Completed - Hepatic Cyst Clinical Trials

Penetration of Cefazolin Into Hepatic Cysts

PENTAC
Start date: December 2014
Phase: N/A
Study type: Interventional

Hepatic cysts are fluid-filled cavities located in the liver parenchyma. They are usually asymptomatic, but can cause mass-related symptoms as abdominal pain, dyspnea and nausea. Aspiration sclerotherapy is indicated in patients with a dominant hepatic cyst to alleviate symptoms by draining the hepatic cyst to reduce cyst diameter. Spontaneous cyst infection, or following aspiration sclerotherapy, presents a severe complication of hepatic cystic disease requiring frequent hospitalization, long-term antibiotic treatment, and in some invasive therapies. Evidence that antibiotics are able to reach adequate intracystic concentration is however lacking. To prevent procedure-related cyst infection in patients receiving aspiration sclerotherapy, cefazolin prophylaxis is given as standard of care. In this study we want to assess the hepatic cyst penetration capacity of cefazolin by comparing serum and cyst fluid concentrations of cefazolin. We hypothesize that cefazolin is able to penetrate hepatic cysts, with treatment naïve cyst allowing a better penetration, reducing the risk of developing cyst infection following aspiration sclerotherapy.